Balloon-based adjuvant radiotherapy in breast cancer: comparison between 99mTc and HDR 192Ir

• Main Authors: Tarcísio Passos Ribeiro de Campos, Carla Flavia de Lima, Ethel Mizrahy Cuperschmid
• Format: Article
• Language: English
• Published: Colégio Brasileiro de Radiologia e Diagnóstico por Imagem 2016-04-01
• Series: Radiologia Brasileira
• Subjects: Braquiterapia de mama; Balão; Reforço de dose; Radioterapia adjuvante; 99mTc; 192Ir; Método Monte Carlo
• Online Access: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-39842016000200009&lng=en&tlng=en

Abstract Objective: To perform a comparative dosimetric analysis, based on computer simulations, of temporary balloon implants with 99mTc and balloon brachytherapy with high-dose-rate (HDR) 192Ir, as boosts to radiotherapy. We hypothesized that the two techniques would produce equivalent doses under pre-established conditions of activity and exposure time. Materials and Methods: Simulations of implants with 99mTc-filled and HDR 192Ir-filled balloons were performed with the Siscodes/MCNP5, modeling in voxels a magnetic resonance imaging set related to a young female. Spatial dose rate distributions were determined. In the dosimetric analysis of the protocols, the exposure time and the level of activity required were specified. Results: The 99mTc balloon presented a weighted dose rate in the tumor bed of 0.428 cGy.h-1.mCi-1 and 0.190 cGyh-1.mCi-1 at the balloon surface and at 8-10 mm from the surface, respectively, compared with 0.499 and 0.150 cGyh-1.mCi-1, respectively, for the HDR 192Ir balloon. An exposure time of 24 hours was required for the 99mTc balloon to produce a boost of 10.14 Gy with 1.0 Ci, whereas only 24 minutes with 10.0 Ci segments were required for the HDR 192Ir balloon to produce a boost of 5.14 Gy at the same reference point, or 10.28 Gy in two 24-minutes fractions. Conclusion: Temporary 99mTc balloon implantation is an attractive option for adjuvant radiotherapy in breast cancer, because of its availability, economic viability, and similar dosimetry in comparison with the use of HDR 192Ir balloon implantation, which is the current standard in clinical practice.